Details for Patent: 9,238,029

Which drugs does patent 9,238,029 protect, and when does it expire?

Patent 9,238,029 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

This patent has eight patent family members in five countries.

Summary for Patent: 9,238,029

Title:	Multiple PPI dosage form
Abstract:	Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
Inventor(s):	Rajneesh Taneja, Majid Vakilynejad
Assignee:	Takeda Pharmaceuticals USA Inc
Application Number:	US13/874,219
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 9,238,029

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	AB	RX	Yes	No	9,238,029		Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-002	Jan 30, 2009	AB	RX	Yes	Yes	9,238,029		Y
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016		DISCN	Yes	No	9,238,029		Y

International Family Members for US Patent 9,238,029

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005264864
Canada	2570916
European Patent Office	1768668
Japan	2008503455